A Phase II Study of 9-Amino-20(S)-Camptothecin (9-AC) (NSC 603071) and Evaluation of Drug Resistance in Patients With Advanced Renal Cell Carcinoma
OBJECTIVES: I. Determine the response rate, duration of response, and survival of patients
with advanced renal cell carcinoma treated with aminocamptothecin colloidal dispersion. II.
Determine the nature and degree of toxicity of aminocamptothecin in this patient population.
OUTLINE: Patients receive aminocamptothecin colloidal dispersion intravenously for 120 hours
weekly for 2 weeks followed by 1 week of rest. Courses are repeated every 3 weeks in the
absence of disease progression or dose limiting toxicity. Patients are followed every 3
months for the first 2 years, every 6 months for the next 3 years, and yearly thereafter.
PROJECTED ACCRUAL: A total of 10-29 patients will be accrued for this study within 2 years.
Primary Purpose: Treatment
Thomas Keane, MD
Winship Cancer Institute of Emory University
United States: Federal Government
|Emory University Hospital - Atlanta||Atlanta, Georgia 30322|
|Emory University School of Medicine||Atlanta, Georgia 30322|